Lantern Pharma (LTRN) vs Passage Bio (PASG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Passage Bio (PASG) has outperformed Lantern Pharma (LTRN) over the past year, losing 54.3% versus a loss of 81.9%. Over five years, LTRN leads with a -91.7% price change compared with -98.1% for PASG. Lantern Pharma is the larger company by market cap ($12.4 million vs $12.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LTRN | PASG |
|---|---|---|
| Share price | $0.83 | $3.78 |
| Market cap | $12.40M | $12.16M |
| 1-day change | -8.79% | -1.95% |
| YTD return | -72.61% | -67.97% |
| 1-year return | -81.92% | -54.35% |
| 5-year return | -91.71% | -98.06% |
| EPS (TTM) | $-1.50 | $-11.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.68 | $20.00 |
| 52-week low | $0.83 | $3.29 |
| Distance from 52-week high | -82.26% | -81.10% |
| Analyst consensus | none | buy |
| Avg. price target upside | +2008.43% | +310.05% |
| Average volume | 180.42K | 26.11K |
| Shares outstanding | 14.94M | 3.22M |
| Employees | 16 | 24 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PASG has outperformed LTRN by 27.6 percentage points over the past year.
About Lantern Pharma
LTRN stock →Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Healthcare · Biotechnology · 16 employees
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Healthcare · Biotechnology · 24 employees
LTRN vs PASG FAQ
Which is bigger, Lantern Pharma or Passage Bio?
Lantern Pharma (LTRN) is larger, with a market capitalization of $12.40M compared with $12.16M for Passage Bio (PASG).
Which stock has performed better over the past year, LTRN or PASG?
PASG returned -54.35% over the past 12 months, compared with -81.92% for LTRN (price return, excluding dividends). Past performance does not predict future results.
Are Lantern Pharma and Passage Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.